Patiromer and Spironolactone in Resistant Hypertension and Advanced CKD: Analysis of the Randomized AMBER Trial
| Autor: | Patrick Rossignol, Jeffrey Budden, Martha Mayo, Rajiv Agarwal, William B. White, Bryan Williams, Susan Arthur |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Drug
medicine.medical_specialty Hyperkalemia Polymers media_common.quotation_subject Original Investigations Spironolactone chemistry.chemical_compound Mineralocorticoid receptor Internal medicine Humans Medicine Renal Insufficiency Chronic media_common Ejection fraction business.industry Patiromer General Medicine medicine.disease Clinical trial chemistry Heart failure Hypertension medicine.symptom business |
| Zdroj: | Kidney360 |
| ISSN: | 2641-7650 |
| Popis: | BACKGROUND: Mineralocorticoid receptor antagonists reduce mortality in patients with heart failure with reduced ejection fraction and have become a standard of care in those with resistant hypertension (rHTN). Yet, their use is limited among patients with CKD, primarily due to hyperkalemia. METHODS: AMBER was a multicenter, randomized, double-blind, placebo-controlled, parallel-group study that reported that the use of the potassium-binding drug patiromer allowed a more persistent use of spironolactone in patients with CKD and rHTN. In this report, we compare the safety and efficacy of patiromer in advanced CKD as a prespecified analysis. RESULTS: Of the 295 patients randomized, 66 fell into the eGFR 25 to |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|